Save information for later
Sign Up

Learn About Inclusion Body Myositis

What is the definition of Inclusion Body Myositis?
Inclusion body myositis (IBM) is a progressive muscle disorder characterized by muscle inflammation, weakness, and atrophy (wasting). It is a type of inflammatory myopathy. The most common symptoms include progressive weakness of the legs, arms, fingers, and wrists. Some people also have weakness of the facial muscles (especially muscles controlling eye closure), or difficulty swallowing (dysphagia). Muscle cramping and pain are uncommon, but have been reported in some people. The underlying cause of IBM is poorly understood and likely involves the interaction of genetic, immune-related, and environmental factors. Some people may have a genetic predisposition to developing IBM, but the condition itself typically is not inherited.
What are the alternative names for Inclusion Body Myositis?
  • Inclusion body myositis
  • IBM
  • Inflammatory myopathy
  • Sporadic inclusion body myositis
Who are the top Inclusion Body Myositis Local Doctors?
Richard Barohn
Elite in Inclusion Body Myositis
Elite in Inclusion Body Myositis

Office

3599 Rainbow Blvd, 
Kansas City, KS 
Recognized by The Myositis Association
Languages Spoken:
English

Richard Barohn is a Neurologist in Kansas City, Kansas. Dr. Barohn is rated as an Elite provider by MediFind in the treatment of Inclusion Body Myositis. His top areas of expertise are Inclusion Body Myositis, Myositis, Myasthenia Gravis, Thymectomy, and Tissue Biopsy.

Lisa Christopher
Elite in Inclusion Body Myositis
Elite in Inclusion Body Myositis

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue, Bayview Medical Offices, Level 01 (G), Clinic 5, Bayview Medical Offices, Level 01 (G), Clinic 5, 
Baltimore, MD 
Recognized by The Myositis Association
Languages Spoken:
English
Offers Telehealth

Dr. Christopher-Stine is the Co-Founder and Director of the Johns Hopkins Myositis Center. She is a Professor of Medicine and Neurology. She is a longstanding core faculty member of the Johns Hopkins University School of Medicine College Advisory Program and serves as the Co-Chair of the Johns Hopkins Institutional Review Board (IRB 5). Dr. Christopher-Stine graduated Cum Laude with a B.A. in chemistry from Franklin and Marshall College; was elected to Alpha Omega Alpha at Hahnemann University School of Medicine, where she received her MD degree, and she attained her Masters of Public Health degree from the Johns Hopkins Bloomberg School of Public Health. Her internship and residency training were completed at MCP Hahnemann University, where she also served as Chief Resident. She pursued her rheumatology fellowship training at Johns Hopkins. Dr. Christopher is rated as an Elite provider by MediFind in the treatment of Inclusion Body Myositis. Her top areas of expertise are Myositis, Polymyositis, Dermatomyositis, and Inclusion Body Myositis.

 
 
 
 
Learn about our expert tiers
Learn More
Andrew L. Mammen
Elite in Inclusion Body Myositis
Neuromusculoskeletal Medicine | Neurology
Elite in Inclusion Body Myositis
Neuromusculoskeletal Medicine | Neurology

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue, Bayview Medical Offices, Level 01 (G), Clinic 5, Bayview Medical Offices, Level 01 (G), Clinic 5, 
Baltimore, MD 
Recognized by The Myositis Association
Languages Spoken:
English

Andrew Mammen is a Neuromusculoskeletal Medicine specialist and a Neurologist in Baltimore, Maryland. Dr. Mammen is rated as an Elite provider by MediFind in the treatment of Inclusion Body Myositis. His top areas of expertise are Myositis, Polymyositis, Dermatomyositis, and Necrotizing Myopathy (NM).

What are the latest Inclusion Body Myositis Clinical Trials?
Blocking Interferon-γ by Ruxolitinib for Treating Inclusion Body Myositis: a Phase IIb Trial

Summary: Refer to the Detailed Description section.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Summary: To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center